# Compounded semaglutide: storage, labeling and sterility questions

What to clarify about a compounded semaglutide shipment, including the pharmacy, storage instructions and signs of a delivery problem.

Canonical: https://velri.co/blog/compounded-semaglutide-sterility-standards-plus-size-first-timer
Publisher: Velri (https://velri.co/about)
Published: 2026-07-01
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

A compounded semaglutide shipment should be traceable to its dispensing pharmacy and accompanied by clear product and storage information. Those details matter because contamination, preparation errors and poor handling can affect medication quality. [1][2]

Compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness or quality before marketing. [3]

## Sterility is a preparation and handling issue

For an injectable medication, sterility concerns contamination by microorganisms. FDA has identified insanitary conditions at compounding facilities and investigated serious harm from contaminated compounded drugs. [1]

A clear-looking liquid or an intact vial does not establish how it was prepared. The relevant information comes from the pharmacy, its oversight and the procedures applicable to the preparation.

The pharmacy can explain how the product should be stored, what the label's dates mean and whom to contact if packaging or instructions are unclear. FDA identifies inadequate labeling as another potential problem with compounded products. [1]

## Shipping conditions can affect quality

FDA has received complaints about compounded GLP-1 medicines arriving warm or with inadequate cooling. The agency advises against using injectable GLP-1 drugs that arrive warm or without sufficient refrigeration because quality may be affected. [2]

That makes a delivery problem a question for the dispensing pharmacy, not something to resolve by guessing from another product's instructions. Refrigerating a questionable shipment after arrival does not answer what happened in transit.

The product's own storage information and the pharmacy's response should address the specific shipment.

## After a multidose vial is first used

FDA recommends discarding multidose vials of compounded GLP-1 medication within 28 days after first use, even if medication remains or the compounder gives a longer period. Each dose requires a new sterile needle and syringe. [2]

## The label should make the prescription understandable

Different concentrations and vial presentations can create confusion. FDA has received reports of serious errors involving measurement of compounded semaglutide, including errors by patients and health professionals. [2]

The prescribed instructions, product concentration and supplied measuring equipment need to be clear together. This is a point for direct clarification with the prescriber or pharmacist; an online conversion example is not a substitute for that clarification.

## Keep the contact details with the order

The pharmacy's name, label, packaging information and order record help identify the preparation if a question arises later. FDA also accepts reports of medication-related adverse events and quality problems through MedWatch. [2]

## Sources
[1] Understanding the Risks of Compounded Drugs | FDA. https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs
[2] FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
[3] Compounding and the FDA: Questions and Answers | FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support